ScholarIQanswers from OpenAlex & ORCID
Sara A. Hurvitz
ResearcherPublications, citations & collaboration network
Sara A. Hurvitz is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Sara A. Hurvitz have?
ScholarIQindexed works
Sara A. Hurvitz has 711 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Sara A. Hurvitz have?
ScholarIQcitation count
Sara A. Hurvitz has 32,230 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Sara A. Hurvitz?
ScholarIQh-index
Sara A. Hurvitz has an h-index of 77 in OpenAlex.
What is the i10-index of Sara A. Hurvitz?
ScholarIQi10-index
Sara A. Hurvitz has an i10-index of 252 in OpenAlex.
What is the ORCID of Sara A. Hurvitz?
ScholarIQorcid
The ORCID for Sara A. Hurvitz is on the source record.
What is the OpenAlex record for Sara A. Hurvitz?
ScholarIQopenalex
The OpenAlex for Sara A. Hurvitz is on the source record.
What are the most-cited papers on Sara A. Hurvitz?
ScholarIQmost cited works
Talazoparib in Patients with Advanced Breast Cancer and a Germline <i>BRCA</i> Mutation
Jennifer K. Litton, Hope S. Rugo, Johannes Ettl, Sara A. Hurvitz, Anthony Gonçalvès, Kyung-Hun Lee, Louis Fehrenbacher, Rinat Yerushalmi, Lida A. Mina, Miguel Martín, Henri Roché, Young‐Hyuck Im, Ruben G.W. Quek, Denka Markova, Iulia Cristina Tudor, Alison L. Hannah, W. Eiermann, Joanne L. Blum
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Aditya Bardia, Sara A. Hurvitz, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam Brufsky, Sagar Sardesai, Kevin Kalinsky, Amelia Zelnak, Robert Weaver, Tiffany A. Traina, Florence Dalenc, Philippe Aftimos, Filipa Lynce, Sami Diab, Javier Cortés, Joyce O’Shaughnessy, Véronique Dièras, Cristiano Ferrario, Peter Schmid, Lisa A. Carey, Luca Gianni, Martine Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, Hope S. Rugo
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
Alessandra Gennari, Fabrice André, Carlos H. Barrios, Javier Cortés, Evandro de Azambuja, A. DeMichele, Rebecca Dent, Deborah Fenlon, Joseph Gligorov, Sara A. Hurvitz, Seock‐Ah Im, David Krug, Wolfgang G. Kunz, Sherene Loi, Frédérique Penault‐Llorca, Jens Ricke, Mark E. Robson, Hope S. Rugo, Cristina Saura, Peter Schmid, Christian F. Singer, Tanja Španić, Sara M. Tolaney, Nicholas C. Turner, Giuseppe Curigliano, Sibylle Loibl, Shani Paluch–Shimon, Nadia Harbeck
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Rashmi K. Murthy, Sherene Loi, Alicia Okines, Elisavet Paplomata, Erika Hamilton, Sara A. Hurvitz, Nancy U. Lin, Virginia F. Borges, Vandana G. Abramson, Carey K. Anders, Philippe L. Bédard, Mafalda Oliveira, Erik Jakobsen, Thomas Bachelot, Shlomit Strulov Shachar, Volkmar Müller, Sofía Braga, François P. Duhoux, Richard Greil, David Cameron, Lisa A. Carey, Giuseppe Curigliano, Karen A. Gelmon, Gabriel N. Hortobágyi, Ian E. Krop, Sibylle Loibl, Mark D. Pegram, Dennis J. Slamon, Maria Corinna Palanca-Wessels, Luke Walker, Wentao Feng, Eric P. Winer
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
William J. Gradishar, Meena S. Moran, Jame Abraham, Rebecca Aft, Doreen M. Agnese, Kimberly H. Allison, Bethany Anderson, Harold J. Burstein, Helen K. Chew, Chau T. Dang, Anthony Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Sara A. Hurvitz, Steven J. Isakoff, Rachel C. Jankowitz, Sara H. Javid, Jairam Krishnamurthy, Marilyn Leitch, Janice A. Lyons, Joanne Mortimer, Sameer A. Patel, Lori J. Pierce, Laura H. Rosenberger, Hope S. Rugo, Amy M. Sitapati, Karen L. Smith, Mary Lou Smith, Hatem Soliman, Erica Stringer-Reasor, Melinda L. Telli, John H. Ward, Kari B. Wisinski, Jessica Young, Jennifer L. Burns, Rashmi Kumar